

S1 Table. Results based on respondents' demographics

Definition

Q1. What do you think is an upper limit of the number of involved organs to be regarded as oligometastasis?

	Total	New patients < 30	New patients ≥ 30	p-value	Experience < 10 yr	Experience ≥ 10 yr	p-value		
Do not consider	36	15 (22.1)	21 (31.3)	0.411	16 (23.9)	20 (29.4)	0.97		
2 or less	38	23 (33.8)	15 (22.4)		20 (29.9)	18 (26.5)			
3 or less	39	19 (27.9)	20 (29.9)		19 (28.4)	20 (29.4)			
5 or less	8	4 (5.9)	4 (6.0)		4 (6.0)	4 (5.9)			
Others	2	0	2 (3.0)		1 (1.5)	1 (1.5)			
Skipped	12	7 (10.3)	5 (7.5)		7 (10.4)	5 (7.4)			

*Excluded the respondents who have chosen four or more subspecialties.

	Total	OMD cases < 10	OMD cases ≥ 10	p-value	Breast	Lung	Prostate	Colorectal	p-value
Do not consider	36	13 (24.5)	23 (28.0)	0.634	16 (32.7)	10 (28.6)	11 (36.7)	10 (31.3)	N/A
2 or less	38	14 (26.4)	24 (29.3)		11 (22.4)	11 (31.4)	8 (26.7)	7 (21.9)	
3 or less	39	16 (30.2)	23 (28.0)		15 (30.6)	10 (28.6)	8 (26.7)	11 (34.4)	
5 or less	8	3 (5.7)	5 (6.1)		1 (2.0)	1 (2.9)	1 (3.3)	1 (3.1)	
Others	2	0	2 (2.4)		1 (2.0)	0	1 (3.3)	1 (3.1)	
Skipped	12	7 (13.2)	5 (6.1)		5 (10.2)	3 (8.6)	1 (3.3)	2 (6.3)	

Q2. What do you think is an upper limit of the number of metastases to be regarded as oligometastasis?

	Total	New patients < 30	New patients ≥ 30	p-value	Experience < 10 yr	Experience ≥ 10 yr	p-value		
Do not consider	6	4 (6.7)	2 (3.3)	0.415	2 (3.0)	4 (5.9)	0.466		
3 or less	32	16 (26.7)	16 (26.2)		14 (20.9)	18 (26.5)			
5 or less	79	40 (66.7)	39 (63.9)		41 (61.2)	38 (55.9)			
10 or less	4	0	4 (6.6)		1 (1.5)	3 (4.4)			
Others	2	1 (1.5)	1 (1.5)		2 (3.0)	0			
Skipped	12	7 (10.3)	5 (7.5)		7 (10.4)	5 (7.4)			

	Total	OMD cases < 10	OMD cases ≥ 10	p-value	Breast	Lung	Prostate	Colorectal	p-value
Do not consider	36	3 (5.7)	3 (3.7)	0.272	2 (4.1)	2 (5.7)	2 (6.7)	3 (9.4)	N/A
3 or less	38	11 (20.8)	21 (25.6)		10 (20.4)	10 (28.6)	7 (23.3)	6 (18.8)	
5 or less	39	32 (60.4)	47 (57.3)		29 (59.4)	18 (51.4)	18 (60.0)	19 (59.4)	

10 or less	8	0	4 (4.9)		1 (2.0)	1 (2.9)	0	1 (3.1)
Others	2	0	2 (2.4)		2 (4.1)	1 (2.9)	2 (6.7)	1 (3.1)
Skipped	12	7 (13.2)	5 (6.1)		5 (10.2)	3 (8.6)	1 (3.3)	2 (6.3)

Q3. What do you think is an upper limit of the size of metastatic tumors to be regarded as oligometastasis?

	Total	New patients < 30	New patients ≥ 30	p-value	Experience < 10 yr	Experience ≥ 10 yr	p-value		
Do not consider	62	25 (36.8)	37 (55.2)	0.196	36 (53.7)	26 (38.2)	0.15		
2 cm or less	6	4 (5.9)	2 (3.0)		2 (3.0)	4 (5.9)			
3 cm or less	23	15 (22.1)	7 (10.4)		11 (16.4)	11 (16.2)			
5 cm or less	31	17 (25.0)	15 (22.4)		10 (14.9)	22 (32.4)			
Others	0	0	1 (1.5)		1 (1.5)	0			
Skipped	12	7 (10.3)	5 (7.5)		7 (10.4)	5 (7.4)			
	Total	OMD cases < 10	OMD cases ≥ 10	p-value	Breast	Lung	Prostate	Colorectal	p-value
Do not consider	62	24 (45.3)	38 (46.3)	0.673	26 (53.1)	18 (51.4)	12 (40.0)	16 (50.0)	N/A
2 cm or less	6	3 (5.7)	3 (3.7)		2 (4.1)	2 (5.7)	1 (3.3)	2 (6.3)	
3 cm or less	23	8 (15.1)	14 (17.1)		9 (18.4)	4 (11.4)	8 (26.7)	6 (18.8)	
5 cm or less	31	11 (20.8)	21 (25.6)		6 (12.2)	8 (22.9)	8 (26.7)	5 (15.6)	
Others	0	0	1 (1.2)		1 (2.0)	0	0	1 (3.1)	
Skipped	12	7 (13.2)	5 (6.1)		5 (10.2)	3 (8.6)	1 (3.3)	2 (6.3)	

Role of local therapy

Q1. Do you think there is a role for local therapy in oligometastatic disease?

	Total	New patients < 30	New patients ≥ 30	p-value	Experience < 10 yr	Experience ≥ 10 yr	p-value		
Yes	101	49 (72.1)	52 (77.6)	0.782	52 (77.6)	49 (72.1)	0.441		
No	1	1 (1.5)	0		0	1 (1.5)			
Not proven	3	2 (2.9)	1 (1.5)		2 (3.0)	1 (1.5)			
Depends on cancer types	18	9 (13.2)	9 (13.4)		6 (9.0)	12 (17.6)			
Skipped	12	7 (10.3)	5 (7.5)		7 (10.4)	5 (7.4)			
	Total	OMD cases < 10	OMD cases ≥ 10	p-value	Breast	Lung	Prostate	Colorectal	p-value
Yes	101	33 (62.3)	68 (82.9)	0.065	36 (73.5)	28 (80.0)	25 (83.3)	26 (81.3)	N/A
No	1	0	1 (1.2)		1 (2.0)	0	0	1 (3.1)	
Not proven	3	2 (3.8)	1 (1.2)		2 (4.1)	1 (2.9)	0	1 (3.1)	

Depends on cancer types	18	11 (20.8)	7 (8.5)		5 (10.2)	3 (8.6)	4 (13.3)	2 (6.3)	
Skipped	12	7 (13.2)	5 (6.1)		5 (10.2)	3 (8.6)	1 (3.3)	2 (6.3)	
Classification and clinical application									
Q1. Are you aware of ESTRO/EORTC classification as following? (Genuine OMD, Repeat OMD, Induced OMD, Oligorecurrence, Oligopersistence, Oligoprogression)									
	Total	New patients < 30	New patients ≥ 30	p-value	Experience < 10 yr	Experience ≥ 10 yr			
Yes	88	38 (55.9)	50 (74.6)	0.051	47 (70.1)	41 (60.3)			0.133
No	32	23 (33.8)	11 (16.4)		12 (17.9)	22 (32.4)			
Skipped	13	7 (10.3)	6 (9.0)		8 (11.9)	5 (7.4)			
	Total	OMD cases < 10	OMD cases ≥ 10	p-value	Breast	Lung	Prostate	Colorectal	p-value
Yes	88	29 (54.7)	59 (72.0)	0.118	30 (61.2)	27 (77.1)	19 (63.3)	20 (62.5)	N/A
No	32	17 (32.1)	17 (20.7)		13 (26.5)	5 (14.3)	10 (33.3)	10 (31.3)	
Skipped	13	7 (13.2)	6 (7.3)		6 (12.2)	3 (8.6)	1 (3.3)	2 (6.3)	
Q2. Do you use ESTRO/EORTC classification in clinical practice?									
	Total	New patients < 30	New patients ≥ 30	p-value	Experience < 10 yr	Experience ≥ 10 yr			
Yes	39	15 (22.1)	24 (35.8)	0.092	19 (28.4)	20 (29.4)			0.587
No	51	25 (36.8)	26 (38.8)		28 (41.8)	23 (33.8)			
Skipped	45	28 (41.2)	17 (25.4)		20 (29.9)	25 (36.8)			
	Total	OMD cases < 10	OMD cases ≥ 10	p-value	Breast	Lung	Prostate	Colorectal	p-value
Yes	88	12 (22.6)	27 (32.9)	0.125	12 (24.5)	12 (34.3)	10 (33.3)	12 (37.5)	N/A
No	32	18 (34.0)	33 (40.2)		18 (36.7)	15 (42.9)	9 (30.0)	8 (25.0)	
Skipped	13	23 (43.4)	22 (26.8)		19 (38.8)	8 (22.9)	11 (36.7)	12 (37.5)	

Values are presented as number (%). EORTC, European Organisation for Research and Treatment of Cancer; ESTRO, European Society for Radiotherapy and Oncology; N/A, not available; OMD, oligometastatic disease.